Zhu Xiaohui, Wu Xin, Cheng Jing, Liao Hongbo, Di Xiaoqing, Li Lili, Li Rong, Zhou Yanfang, Zhang Xiangning
Department of Pathophysiology, Guangdong Medical University, Zhanjiang 524023, Guangdong, China.
Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang 524023, Guangdong, China.
Oncotarget. 2017 Jul 18;8(29):47755-47766. doi: 10.18632/oncotarget.17766.
Hepatocellular carcinoma (HCC) is a highly malignant tumor, and the main cause of treatment failure is malignant proliferation. Aberrations in Wnt/β-catenin signaling are associated with HCC development. Despite the improvements in overall survival made over the past decade from the advent of molecularly targeted therapies, these treatments do not have efficacy in all patients with different pathogeneses. Therefore, there is a demand for novel chemotherapeutic agents for HCC. To this end, we built a natural compound library and screened out a rotenoid named dalbinol from the seeds of Amorpha fruticosa L. Our data demonstrated that dalbinol inhibited the growth of HepG2, HepG2/ADM and Huh7 cells in a concentration-dependent manner. Pharmacological experiments also showed that dalbinol suppressed growth and induced apoptosis in these HCC cell lines in vitro. Furthermore, we found that dalbinol promoted β-catenin degradation, which was mediated by the ubiquitin-proteasome pathway. To summarize, our results illustrate that dalbinol inhibited HCC cell growth by facilitating β-catenin degradation through the ubiquitin-proteasome pathway. Hence, we propose that dalbinol will be a promising agent for the treatment of HCC subtypes with aberrant Wnt/β-catenin pathway activation.
肝细胞癌(HCC)是一种高度恶性的肿瘤,治疗失败的主要原因是恶性增殖。Wnt/β-连环蛋白信号通路异常与HCC的发生发展相关。尽管过去十年分子靶向治疗的出现使总体生存率有所提高,但这些治疗方法并非对所有具有不同发病机制的患者都有效。因此,需要开发新型的HCC化疗药物。为此,我们构建了一个天然化合物库,并从紫穗槐种子中筛选出一种名为达比诺醇的鱼藤酮类化合物。我们的数据表明,达比诺醇以浓度依赖性方式抑制HepG2、HepG2/ADM和Huh7细胞的生长。药理学实验还表明,达比诺醇在体外抑制这些HCC细胞系的生长并诱导其凋亡。此外,我们发现达比诺醇促进β-连环蛋白的降解,这是由泛素-蛋白酶体途径介导的。综上所述,我们的结果表明,达比诺醇通过泛素-蛋白酶体途径促进β-连环蛋白降解从而抑制HCC细胞生长。因此,我们认为达比诺醇有望成为治疗Wnt/β-连环蛋白途径异常激活的HCC亚型的药物。